The GP margin on the product is likely to be quite healthy but of primary importance in the first instance will be gaining reimbursement for the product. That will drive sales and push COGS down. Let's all wish for widespread clinical acceptance.
Ann: Half Year Report and Accounts, page-18
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$3.17 |
Change
0.180(6.02%) |
Mkt cap ! $223.2M | |||
| Open | High | Low | Value | Volume |
| $3.17 | $3.18 | $3.12 | $1.124M | 356.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 410 | $3.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $3.17 | 2434 | 1 |
View Market Depth
| Last trade - 16.10pm 03/10/2024 (20 minute delay) ? |
| AVH (ASX) Chart |